A Phase 2, Open-Label, Multi-Center Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

Trial Profile

A Phase 2, Open-Label, Multi-Center Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

Recruiting
Phase of Trial: Phase II

Latest Information Update: 31 Aug 2017

At a glance

  • Drugs Carfilzomib (Primary) ; Dexamethasone (Primary) ; Venetoclax (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Sponsors AbbVie
  • Most Recent Events

    • 28 Aug 2017 Planned End Date changed from 1 Nov 2020 to 22 Dec 2020.
    • 28 Jun 2017 Planned End Date changed from 25 Nov 2021 to 1 Nov 2020.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top